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COMPOSITIONS COMPRISING HUMAN
IMMUNODEFICIENCY VIRUS TAT
ADSORBED TO THE SURFACE OF ANIONIC
NANOPARTICLES

Tat is released from cells at relatively high levels and can be
detected in the serum of HIV infected individuals. It is rapidly

taken up by other cells through binding mediated by the basic
domain of the molecule (Ma, M. and Nath, A. 1997 J. Virol.
71:2495). This feature alloWs extracellular Tat to transacti
vate latent HIV in other cells (Frankel, A. D. and Pabo C. O.,
1998 Cell 55: 1 189; Li, C. J. et al. 1997 Proc. Natl. Acad. Sci.
USA 94:8116). It also alloWs for Tat to transactivate other
cellular processes, causing altered intracellular signaling in a
variety ofcell types (Li, C. J. et al. 1997 Proc. Natl. Acad. Sci.
USA 94:8116;Viscidi, R. P. etal. 1989 Science 246: 1 606; Li,
C. J. et al. 1995 Science 268:429; Westendorp, M. O. et al.
1995 Nature 375:497; Kolesnitchenko, V. et al. 1997 J. Virol.

RELATED APPLICATIONS

This application is a US. National Phase under 35 U.S.C.
371 of PCT.US03/05806 ?led Feb. 27, 2003, Which in turn
claims the bene?t of US. Provisional application No. 60/ 361 ,
043, ?led on Mar. 1, 2002 the entire contents of each of Which

are hereby incorporated by reference.
FIELD OF THE INVENTION

71:9753). A consequence of these events is severe immuno
suppressive. HoWever, most of these studies have been con
ducted in vitro at nanomolar concentrations of Tat, and it is
unclear to What extent this occurs in vivo. Extracellular Tat
also causes rapid calcium ?uxes in neurons and other cell

The present invention relates to therapeutic agents and
methods for treating HIV infection. More speci?cally, the
invention relates to compositions of matter that include an

immunostimulatory recombinant transcriptional Tat protein
of the HIV and a Tat-adsorbed nanoparticle that evoke

20

T-helper (Th), cytotoxic T-lymphocyte (CTL), and antibody
immune responses.
BACKGROUND OF THE INVENTION
25

The human immunode?ciency virus (HIV) is a member of
the lentivirus family of animal retroviruses. Lentiviruses,

including visna virus of sheep, and the bovine, feline and
simian immunode?ciency viruses (SIV), are capable of long
term latent infection in cells and short-term cytopathic

consisting of amino acids 49 to 57 of Tat Was shoWn to
30

effects, and they all produce sloWly progressive, fatal dis
eases, Which include Wasting syndromes and central nervous

system degeneration. TWo closely related types of HIV, des
ignated HIV-1 and HIV-2, have been identi?ed. HIV-1 and
HIV-2 differ in genomic structure and antigenicity, sharing
only 40 percent nucleic acid sequence homology. Nonethe
less, both forms of HIV cause similar clinical syndromes.
HIV infection ultimately results in impaired function of
both the speci?c and innate immune systems. The most
prominent defects are in cell-mediated immunity and they

types (Nath, A. et al. 1996 J. Virol. 70:1475; Nath, A. et al.
1996 J. Neurovirol. 2:17; Holden, C. P. et al. 1999 Neuro
science 91:1369; Haughney, N. J. et al. 1998 J. Neurovirol.
4:353; Nath, A. et al. 2000 Ann. Neurol. 47 (January 2000);
Haughney, N. J. et al. 1999 J. Neurochem. 73:1363).
Interestingly, this rapid internaliZation of Tat also results in
the e?icient entry of Tat into the MHC class I processing
pathWay (Moy, P. et al. 1996 Mol. Biotechnol. 6:105; FaWell,
S. et al. 1994 Proc. Natl. Acad. Sci. USA 91 :664; Kim, D. T.
et al. 1997 J. Immunol. 159:1666). In fact, a single peptide

35

facilitate the transport of ovalbumin (OVA) into the class I
pathWay (Moy, P. et al. 1996 Mol. Biotechnol. 6: 105). Thus,
the internalization of Tat and entry into the class I pathWay
Would be expected to enhance the development of cytotoxic
T-lymphocyte (CTL) responses aimed at Tat epitopes, if its
transactivating activity Were blocked. Inactivation of the
transactivation responses aimed at Tat epitopes has been
achieved by mutating residue Cys 22 to Gly. The mutated Tat
functions as a dominant negative (Rossi, C. et al. 1997 Gene

40

Ther. 4:1261; Caputo, A. et al. 1996 Gene. Ther. 3:235).
Several studies have shoWn that Tat is immuno suppressive.

can be attributed to a lack of CD4+ T cells, and/or abnormali

Tat can induce apoptosis in T cells by a process that involves

ties in immune system function With normal CD4+ T cell
counts. The hallmark of the progression of HIV-induced dis
ease is the diminishing number of CD4+ T cells in the periph
eral blood, from a normal of about 1000/mm3 to less than

activation of cellular cyclin dependent kinases (Li, C. J. et al.
1995 Science 268:429). Recently, Tat has been shoWn to
up-regulate FasL on macrophages (Wu, M. X. and Schloss
45

100/mm3 in fully developedAIDS. Since CD4+ helper T cells
are essential for both cell-mediated and humoral immune

responses to various microbes, the loss of these lymphocytes
is a major reason Why AIDS patients become susceptible to so
many infections. The loss of CD4+ cells may occur after
several months or take longer than 10 years in different indi
viduals.

HIV gene expression may be divided into an early stage,
during Which regulatory genes are expressed, and a late stage,
during Which structural genes are expressed and full-length

50

55

man, S. F. 1997 Pro. Natl. Acad. Sci. USA 94:13832; Dock
rell, D. H. et al. 1998 J. Clin. Invest. 101:2394) and T cells
(Westendorp, M. O. et al. 1995 Nature 375:497), resulting in
apoptosis of the Fas expressing T cells. On the other hand, Tat
has been shoWn to prevent apoptosis in some systems (Zauli,
G. et al. 1993 Cancer Res. 53:4481). HoWever, most ofthese
studies have been conducted in vitro, and it is unclear to What
extent Tat is immunosuppressive in vivo. A recent study by
Cohen et al. (Cohen, S. S. et al. 1999 Proc. Natl. Acad. Sci.
USA 96:10842) has shoWn that immunization using Tat in

complete Freund’s adjuvant (CFA) suppressed the response

viral genomes are packaged. Expression of the early regula

to a co-administered antigen, and that this effect Was abro

tory genes, including Tat, requires sequential RNA splicing

gated by oxidation of the Tat molecule. It Would be desirable
to evaluate the immunosuppressive properties of Tat in an in

events in the nucleus that generate short mRNAs, Which are
then transported to the cytoplasm and are subsequently trans
lated into proteins. The Tat gene encodes a protein that binds

60

to a sequence present in the long terminal repeats (LTR)

called the transactivating response element (TAR), resulting
in enhanced viral gene expression. Binding of the Tat protein
to the viral LTR causes a 1000-fold increase in RNA poly

merase II-catalyZed transcription of the provirus, and is
required for replication of the virus (Abbas, A. K. et al. 1997
in Cellular and Molecular Immunology, ch 21, 450-459).

65

vivo system.
Tat from the human immunode?ciency virus type 1 (HIV
1) is an RNA binding transcriptional protein that is expressed
early in HIV infection, and is necessary for high level expres
sion of viral proteins (Garber, M. E. and Jones, K. A. 1999
Curr. Opin. Immunol. 1 1:460). Tat comprises 86 to 102 amino
acids that are encoded by 2 exons, and Tat protein comprise
?ve functional domains (Bayer, P. et al. 1995 J. Mol. Biol.
247:529). The ?rst 72 amino acids are encoded by exon 1 and

US 7,588,764 B2
3
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exhibit full transactivating activity. The amino terminal
domain spans the ?rst 21 amino acids; the cysteine-rich

prevent the toxic and immunosuppressive effects of Tat
(Gringeri, A. et al. 1998 J. Hum. Virol. 11293; Gallo, R. C.
1999 Proc. Nat. Acad. Sci. USA 9618324; Gringeri, A. et al.
1999 J. Aquir. Immune De?c. Syndr. Hum. Retrovirol.
201371). Tat toxoid has been administered in incomplete Fre
und’s adjuvant to HIV seronegative people, and has been
shoWn to safely induce modest antibody and DTH responses
(Gringeri, A. et al. 1998 J. Hum. Virol. 11293; Gringeri,A. et
al. 1999 J. Aquir. Immune De?c. Syndr. Hum. Retrovirol.

domain spans amino acids 22-37 and represents the transac
tivation domain; the basic domain spans amino acids 49-72,
and contains the nuclear localization signal sequences, Which
facilitate the binding of Tat to Tat-responsive elements as Well
as the uptake of Tat by the cell (Jones, K. A. and Peterlin, B.
M. 1994 Ann. Rev. Biochem. 631717; Chang H. C. et al. 1997
Aids 1111421; Barillari, G. et al. 1993 Proc. Natl. Acad. Sci.
USA 9017941). The second exon encodes the amino acid

201371). HoWever, the use of a denatured molecule may

C-terminal sequence, Which varies among different strains of

destroy important epitopes and prevent Tat from ef?ciently

HIV-1 from amino acids 73 to 86 or 73 to 102. The C terminus
is not required for transactivation but does contain an RGD

entering cells for an optimum immune response. Also, current
immunization strategies Would not be expected to induce T

(arginine-glycine-aspartate) motif, Which is important in

helper 1 (Th1), or CTL responses, Which are critical for
antiviral immune responses. Biologically active Tat has been
used to immuniZe monkeys (Cafaro, A. et al. 1999 Nat. Med.

binding to cell surface molecules and the extracellular matrix
(Chang H. C. et al. 1997 AIDS 1111421). The inventors have
shoWn that the second exon of Tat in?uences the tertiary

51643). This vaccination protocol achieved partial protection

con?guration of Tat and greatly potentiates Tat uptake (Ma,

against the highly pathogenic SHIV virus. HoWever, it is
conceivable that had the immunosuppressive effect of Tat

M. and Nath, A. 1997 J. Virol. 7112495).
Tat is an unusual transcription factor as it can be released

20

from cells and enter cells, While retaining its transactivating

The present inventors have discovered that Tat produced by
recombinant methods tightly binds bacterial RNA, Which

activity, Which enables it to up-regulate a number of genes. It
appears that the basic domain of Tat is important, not only for
translocation and for nuclear localiZation but also for trans

activation of cellular genes. As such, targeting of Tat protein
or, more simply, the basic protein provides great scope for
therapeutic intervention in HIV-1 infection.
Modern vaccines typically consist of either a killed (inac

25

Notwithstanding the considerable success that has been
achieved in creating effective vaccines against numerous dis
eases, AIDS is one disease that is not preventable through the

30

ation of the protein and concomitant loss of important

epitopes. Thus, the conventional puri?cation methodology
results in less-than-optimal immunogenic recombinant Tat

protein.

The task of developing an effective vaccine for immuno

prophylaxis against HIV has been complicated by the genetic
has largely been directed to proteins of the virus that are
expressed on the surface of infected cells, Which are recog
niZed by cytotoxic T cells. The T cell response eliminates
infected cells, While free virus is blocked and cleared by
antibodies to surface antigens of the viron. Limitations of this
mode of vaccination are readily apparent in HIV- 1, Which has

The present inventors have also discovered that highly
puri?ed Tat does not cause immuno-suppression When given
as a vaccine in mice, While still inducing a strong immune
response. Moreover, recombinant Tat has heretofore been

puri?ed by reverse-phase HPLC, Which gives rise to denatur
35

use of traditional vaccines.

potential of the virus for great antigenic variability. This effort

conventional methods of puri?cation of recombinant Tat are
unable to remove from the protein. This tightly bound RNA
tends to mask antigenic sites (epitopes) on the Tat protein.
Stimulation of the immune system by recombinant Tat pro
tein is thereby attenuated, Which in turn reduces the Tat pro
tein’s usefulness as a vaccine.

tivated) or a live, nonvirulent (attenuated) form of an infec

tious agent. Traditionally, the infectious agent is groWn in
culture, puri?ed, and either inactivated or attenuated Without
losing the ability to evoke an immune response that is effec
tive against the virulent form of the infectious organism.

been abolished, a better immune response could have been
attained.

40

Heretofore, Tat has been produced by synthetic proce
dures. While the primary structure (amino acid sequence) of
Tat can be attained by such methodology, the harsh chemical
conditions required for such synthesis tend to interfere With
protein folding. Thus, it has not been heretofore possible to

faithfully produce a Tat protein by synthetic methods that
45

possess naturally occurring Tat protein’ s tertiary structure. As
a result, purely synthetic methods tend to produce Tat protein

demonstrated a great diversity in immunogenic viral epitopes

that lacks some or all of the epitopes that are present in

and rapid mutational variations that occur Within and betWeen
infected individuals.

naturally-occurring Tat protein, again resulting in less-than
optimal immune stimulation by recombinant Tat protein.

On the other hand, intracellular Tat is ef?ciently processed

50

There is thus a need for a method for producing a recom

by major histocompatibility complex (MHC) class 1 for pre

binant Tat protein that possesses a tertiary structure that has

sentation to cytotoxic T lymphocytes (CTL). CTL responses
have been detected repeatedly in individuals infected With
HIV (van Baalen, C. A. et al. 1997 J. Gen. Virol. 7811913;
Venet, A. et al. 1992 J. Immunol. 14812899; Froebel, K. S. et
al. 1994 AIDS Res. Hum. Retroviruses 101S83; Ogg, G. S. et
al. 1998 Science 27912103), and other studies have shoWn
that the presence of anti-Tat CTL during the initial phase of

not been compromised by harsh synthetic chemicals.
There is also a need for a method for producing recombi

nant Tat protein that is free of masking of antigenic sites by
55

immunosuppressive.

infection, correlates inversely With the progression of the
infection to AIDS disease (Re, M. C et al. 1995 J. Aquir.

There is also a need for a recombinant Tat protein that is
60

Immune De?c. Syndr. Hum. Retrovirol. 101408). Tat also
shoWs very little variation betWeen HIV subtypes, and the
?rst exon is highly conserved among the different subtypes,
except the 0 subtype (Gringeri, A. et al. 1998 J. Hum. Virol.
11293). Because of these properties, Tat is an attractive can
didate as a vaccine. Current studies on the development of a
Tat vaccine utiliZe inactivated Tat “toxoid” in an effort to

bacterial RNA.
There is also a need for a recombinant Tat protein that
possesses the ability to be internaliZed by cells and that is not

processed via the MHC class I pathWay.
There is also a need for an effective immunogen and a

method for effectively eliminating Tat-expressing cells by
65

evoking strong Th1 and CTL responses, and resulting in an
effective vaccine against HIV.
Furthermore, protein-based vaccines, such as recombinant
Tat, are often more effective if administered With at least one

adjuvant to enhance their potency (T. W. Baba, V. Liska, A. H.

US 7,588,764 B2
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khimani, N. B. Ray, P. J. Dailey, D. Penninck et al., Nat. Med.
1999 5 194-203). Unfortunately, after decades of research,
insoluble aluminum salts. (generally called as “Alum”) still
represent the only approved adjuvants for human use in the
US (R. K. Gupta, G. R. Siber, 1995 13 1263-1276).Alum has
been used as vaccine adjuvant for many years. However, it is

ated immune responses, including CTL, in mice folloWing
intramuscular immunization (J. KaZZaZ, J. Neidleman, M.
Singh, G. Ott, D. O’Hagan, J. Control. Rel. 2000 67 347-356).
Surface adsorption of vaccines on microparticles has advan
tage in that it avoids the damages to vaccines caused by the
sonication and high-torque mechanical mixing often needed
in the process of microparticle preparation. In addition, limi
tation caused by the sloWness of vaccine release once being
incorporated can also be avoided. Singh et al. (M. Singh, M.
Briones, G. Ott, D. O’Hagan, Proc. Natl. Acad. Sci. 2000 97
811-816) reported that the siZe of PLGA microparticles With
adsorbed pDNA directly related to the strength of the result

not a potent adjuvant for recombinant proteins, and more

importantly, it does not help in cell-mediated immune
responses (R. K. Gupta, E. H. Relyveld, E. B. Lindblad, B.
BiZZini, S. Ben-Efraim, C. K. Gupta, Vaccine. 1993 11 293
306). It is Well knoWn that, With protein-based vaccines, Alum
as adjuvant only helps humoral immune responses, charac
teriZed by enhanced antibody production and the type-2 CD4

ing immune response; Wherein the relative ratio Was 300
nm>1 micron>30 microns. The authors attributed this particle
siZe relationship to the enhanced ability of the smaller par

T helper cell (Th2) responses, such as enhanced release of
cytokines like interleukin 4 (IL-4) and/or the enhanced pro

duction of IgG subtype IgG1 (R. K. Gupta, G. R. Rost, E.
Relyveld, G. R. Siber, Adjuvant properties of aluminum and
calcium compounds, In: M. F. PoWell, M. J. NeWman (Eds.),
Vaccine design: the subunit and adjuvant approach, Plenum
Press, NeW York, 1995, p 229-248). Therefore, there exists a
clear need to develop alternative and improved vaccine adju
vants and/ or delivery systems, especially those that can help
in cell-mediated immune responses, for protein-based vac
cines, such as recombinant Tat protein.
Over the last several decades, many other potential vaccine

ticles to be taken up by antigen presenting cells. Nevertheless,
particles less than 300 nm Were not investigated by the
authors most likely since 300 nm particles that could be

produced using the process described by the authors.
20

As such, there is a need for a method to engineer nanopar
ticles less than 300 nm and even less than 100 nm using a

rapid and reproducible one-step process that may be con
tained in one vessel Wherein said nanoparticles can be used to

more e?iciently target protein antigen to antigen presenting
25

cells. There is also a need for an effective adjuvant and/or

adjuvants have been developed (M. Singh, D. T. O’Hagan,

delivery system for Tat to enhance both humoral and cellular

Nat. Biotech. 1999 17 1075-1081). Some of them Were

Th1-type immune responses.

proven to help in cell-mediated immune responses. LipidA is
one example. The adjuvant effect of the lipopolysaccharide
(LPS) from Salmonella Minnesota R595 (Re) Was ?rst
described as early as in 1956 (J. T. Ulrich, K. R. Myers.

SUMMARY OF THE INVENTION
30

The foregoing and other needs are met by embodiments

Monophosphoryl lipidA as an adjuvant: past experiences and

according to the present invention, Which provide a method of
producing non-denatured, recombinant Tat protein that is free
of bacterial RNA, the method comprising a step for removing

neW directions. In: Vaccine design: The subunit and adjuvant

approach, Ed (M. F. PoWell, M. J. NeWman) Plenum Press,
NeW York, NY 1995 p 495-524). The lipid A region of the
LPS Was found to be responsible for the adjuvanticity. Lipid
A, Which generally aids in Th1-type responses, enhances
immune responses primarily through its ability to activate
antigen-presenting cells (APC) and to induce the release of
cytokines such as interferon-gamma (IFN-y) and IL-2. The

35

ing, Without denaturing, Tat protein.
The foregoing and other needs are met by embodiments
according to the present invention, Which provide a non
denatured, recombinant Tat protein that is free of bacterial
40

strong toxicity of lipid A promoted the development of the
detoxi?ed MPL, Which retains the adjuvant properties of lipid
A but With much reduced side effects (A. J. Johnson, Adju
vant action of bacterial endotoxins on the primary antibody

response. In: M. Landy, W. Braun, (Eds.) Bacterial endotox
ins. NeW BrunsWick: University Press, 1964 pp 252-262; J. R.

45

Baldridge, R. T. Crane, Monophosphoryl lipidA (MPL) for
mulations for the next generation of vaccines, Methods 1999
19 103-107). Besides the immunostimulatory molecules such
as the lipid A, particulates as vaccine adjuvants have been
evaluated for many years (D. T. O’Hagan, M. Singh, R. K.

Tat-delivery system according to the present invention.

55

from the detailed description given beloW. The accompanying
draWings are presented for the purposes of illustration only,
and thus are not intended to limit the scope of the present
invention.
FIG. 1 shoWs Tat binding to RNA. Lane 1 shoWs molecular

sively investigated is the poly (lactide-co-glycolide) (PLGA)

Weight markers. Lane 2 shoWs transfer RNA. Lane 3 shoWs
60

Tat protein (10 ug). Lane 4 shoWs Tat protein treated With
highly puri?ed RNase for 20 min at room temperature.
FIG. 2 shoWs a bar diagram that depicts the speci?c anti
body response of four groups of mice that had been immu

rated into the microparticles for delivery (O’Hagan, 1998).
HoWever, vaccines can also be adsorbed on the microparticles

on their surface Were capable of inducing potent cell-medi

BRIEF DESCRIPTION OF THE DRAWINGS

The present invention Will become more fully understood

microparticle. It has proven to be a potential vaccine adjuvant

(J. Kreuter, P. P. Speiser, Infect. Immun. 1976, 13: 204-210).
For example, KaZZaZ et al. (2000) recently demonstrated that
PLGA microparticles With adsorbed HIV-1 p55 gag protein

The foregoing and other needs are further met by embodi
ments according to the present invention, Which provide a
method for inducing humoral and cellular responses that Will
lead to the destruction of HIV-infected cells, the method
comprising administering to a subject, including a human
subject, a humoral and cellular response inducing amount of

50

lates as a vaccine delivery system. One of the most exten

and/or delivery system for years (D. T. O’Hagan, J. Pharm.
Pharmcol. 1998 59 1-10). Usually, vaccines Were incorpo

RNA.

a recombinant Tat protein With or Without an adjuvant and/or

Gupta, Adv. Drug. Del. Rev. 1998 32 225-246). Particulates,
such as emulsions, microparticles, ISCOMs, liposomes,
virosomes, and the virus-like particles (VLP), have compa
rable dimensions to the pathogens the immune system
evolved to combat. Therefore, it is reasonable to use particu

bacterial RNA from the Tat protein and a method for purify

65

niZed With recombinant Tat 1-72 (SEQ ID NO:1) alone (a),
and in combination With Alum (b), HPC (c), and HPC and
Alum (d), according to the protocol described in Example 1

(a).
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FIG. 3 shows a bar diagram that depicts the induction of Tat
1-72 (SEQ ID NO: 1) speci?c T cell responses from mice that
had been immunized With Tat 1-72 (SEQ ID NO:1). T cell

and CTL responses. In some embodiments according to the

present invention, the inventive Tat protein is administered to
a patient in need of such treatment early in the course of

ug/ml Tat 1-72 (SEQ ID NO:1).

infection, such as during the presymptomatic stage, alone or
in combination With other subunit vaccines. In other embodi
ments, the inventive Tat protein is administered after the
patient has manifested symptoms of HIV infection.
In another aspect of the present invention there is a method
for treating HIV infection. The inventive method comprises
administering a recombinant Tat protein that elicits humoral
and cellular immune responses, While avoiding immune sup

FIG. 5 depicts the results of the How cytometry protocol
outlined in Example 2. The numbers in the upper right quad

pression. The humoral response provides neutraliZing anti
bodies speci?c for Tat, Which eliminates viral Tat protein that

rant represent the percent K11 -26, CD4-cells. ShoWn are the
results from a single mouse for each group. TWo groups of
mice Were tested, and the results of the second group of

is released from HIV-infected cells. The cellular immune
response induces the activation of Th1 and CTL cells, Which
then target and eliminate cells harboring HIV.
The present inventors have surprisingly discovered that

proliferation Was determined in the absence or the presence of
Tat 1-72 (SEQ ID NO: 1) at a concentration of1 ug/ml or 10

5

ug/ml, according to the protocol described in Example 1 (b).
FIG. 4 shoWs the result of an RNAse protection assay that

Was performed according to the protocol outlined in Example
1 (c). The protected RNA fragments correspond to the cytok
ines that are expressed by Tat immune T cells in response to 1

animals (not shoWn) are identical to the results shoWn in FIG.
5.
FIG. 6 shoWs the effect of the concentration of Tat on the

particle siZe ( ) and Zeta potential ( ) of the resulting Tat

recombinant Tat protein tightly binds bacterial RNA, Which
masks Tat epitopes. FIG. 1 shoWs Tat binding to RNA in
20

samples analyZed by agarose gel electrophoresis folloWed by

25

staining With ethidium bromide. The absence of signal in lane
4 suggests that the Tat protein binds to RNA Which has the
molecular mass of transfer RNA (1200 bp). The present
inventors have further discovered that Tat protein copuri?es
With endotoxin, Which may mask Tat epitopes, and/or sup

adsorbed nanoparticles. Data reported Were meanzS. D.

(n:3).
FIG. 7 shoWs the stability of the Tat-adsorbed nanopar
ticles in simulated biological media. The particle siZes Were

measured prior to incubation (White bars) and after incuba

tion (black bars).

press immune function. In a preferred embodiment a recom

FIG. 8 shoWs Tat-speci?c serum IgG (A) and IgM (B)

binant Tat protein is prepared that does not have RNA tightly

levels measured 28 days after the initial immunization of four
groups of mice, (i) mice immuniZed With Tat adjuvanted With
Alum (lighter shaded bars), (ii) mice immuniZed With Tat

bound to it, and that is substantially free of endotoxin con
tamination.
30

adsorbed nanoparticles (NPs) (black bars), (iii) mice immu
nized With Tat adjuvanted to lipid A (darker shaded bars) and

The present inventors have surprisingly discovered that
recombinant Tat protein tightly binds bacterial RNA, Which
masks Tat epitopes. FIG. 1 shoWs Tat binding to RNA in

(iv) naive mice (White bars) Naive mice are indicated by the

samples analyZed by agarose gel electrophoresis folloWed by

Data reported Were meaniS. D. (n:5). * indicates that the
results from the immuniZed mice Were signi?cantly different
from that from the naive mice, Whereas there Was no signi?
cant difference among the three immuniZed groups.

staining With ethidium bromide. The absence of signal in lane
4 suggests that the Tat protein binds to RNA Which has the
molecular mass of transfer RNA (1200 bp). The present
inventors have further discovered that Tat protein copuri?es
With endotoxin, Which may mask Tat epitopes, and/or sup

FIG. 9 shoWs release of cytokines from isolated spleno
cytes recovered from mice immuniZed With either Tat adju
vanted With Alum, Tat adsorbed on nanoparticles (NPs), or
Tat adjuvanted With lipidA on day 0 and day 14. Data reported
Were meaniS. D. (n:3). * indicates the INF-y releases from
the NPs and lipid A groups Were different from that of the
others. ** indicates the INF-y release from the Alum group
Was greater than that from the naive. *** indicates that the
IL-4 release from the NPs Was signi?cantly loWer than that
from the Alum.

FIG. 10 illustrates in vitro proliferation of isolated spleno
cytes recovered from mice immuniZed With either Tat adju
vanted With Alum, Tat adsorbed on nanoparticles (NPs), or
Tat adjuvanted With lipidA on day 0 and day 14. Data reported

35

press immune function. In a preferred embodiment a recom
40

binant Tat protein is prepared that does not have RNA tightly
bound to it, and that is substantially free of endotoxin con
tamination.
The present inventors have discovered that Wild-type Tat

1-72 (SEQ ID NO: 1) is capable of inducing signi?cant and
45

speci?c humoral and T cell mediated immune responses, and
that Tat 1-72 is not immunosuppressive in vivo. The term
“Wild-type” refers to an amino acid sequence encoded by a

50

cDNA that is identical to that encoded by the endogenous
gene. Tat refers to the protein product of the tat gene. In still
another aspect of the present invention there is a recombinant

Tat 1-72 (SEQ ID NO: 1) that faithfully reproduces both the
primary and tertiary structure of naturally occurring, Wild
type Tat 1-72 (SEQ ID NO: 1).

Were meaniS. D. (n:3). * indicates that the result from the
NPs group Was signi?cantly different from that of the others.

While the speci?c embodiments set forth beloW are
DETAILED DESCRIPTION OF THE INVENTION

55

In one aspect of the present invention there is a therapeutic
agent for treating or preventing HIV infection. In some
embodiments according to the present invention, a vaccine is

provided that is capable of eliminating part or all HIV viral
load from an infected host by targeting the immune system to
HIV-infected cells. In some embodiments, the invention is
directed to treating HIV-1 infection.
In some embodiments of the invention, the therapeutic
agent includes an immunostimulatory recombinant Tat pro

60

directed to HIV-1, the puri?cation and therapeutic method
ologies set forth herein are equally applicable to HIV-2,
oWing to the recogniZed homology betWeen the tWo viral
strains. As used in the general discussion of the invention,
“HIV” refers to HIV-1 or HIV-2, unless otherWise speci?ed.
Preferably, some embodiments of the present invention

provide methods for using a recombinant Tat protein for
inducing humoral and cellular responses in an animal, pref
erably a mammalian animal, and more preferably a human.
65

More preferably, the Tat protein is autonomously intemaliZed
by cells; that is, not integrated into the host genome. As

tein that retains the ability of being intemaliZed by cells and

mentioned above, the second exon of Tat in?uences the ter

acts as an effective immunogen for the development of Th1

tiary con?guration of Tat and greatly potentiates Tat cellular
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Th1 cells, by evoking antibody dependant cellular cytotoxic

uptake. Three forms of recombinant Tat proteins Were evalu
ated for their immunogenic effects: Tat 1-86 (SEQ ID NO: 2),
Tat 1-72 (SEQ ID NO: 1), and mutated Tat 1-86 (mTat1-86)

ity or by complement-dependent cell lysis. In a preferred
embodiment, the immunization protocol induces a Th1 and
CTL response to effectively eliminate HIV infected cells that
express viral Tat in vivo. In any case, administering the inven

(SEQ ID NO: 3). Tat 1-72 (SEQ ID NO: 1) protein Was
derived from the HIV-1 BRU exon 1; and Tat 1-86 (SEQ ID
NO: 2) Was derived from HIV-1 BRU exons 1 and 2. The
HIV-1 BRU exons Were obtained from Dr. Richard Gaynor

tive recombinant Tat protein as an antigen to an animal or a

patient infected With HIV, eliminates cells harboring the HIV

through the AIDS repository at the NIH. Mutated Tat 1-86

and restores immune responses lost as a result of the infec

(mTat 1-86) (SEQ ID NO: 3), Which is derived from exon 1,

tion. The method of administering may be oral, topical, nasal

Was modi?ed to contain a single amino acid substitution at

or parenteral. Parenteral administration may include intrave

position 22, Whereby Cys 22 Was substituted by a Gly using

nous, intramuscular, subcutaneous, intraderrnal or intraperi
toneal. Most preferably, the therapeutic agent should be for

site directed mutagenisis (Rossi, C. et al. 1997 Gene Ther.
411261; Caselli, B. et al. 1999 J. Immunol. 16215631). The

mulated so as to be suitable forparenteral administration to an

animal, and to be suitable for treating humans.
Previously developed vaccines have combined the Tat anti
gen With either RIBI or Alum adjuvants, (Cafaro, A. et al.
1999 Nat. Med. 51643), Tat-ovalbumin conjugates (Moy, P. et
al. 1996 Mol. Biotechnol. 61105), or Tat-encapsulated cat

protein mTat 1-86 is a transdominant Tat mutant that lacks
HIV-1 transactivation activity, and has been shoWn to elicit
immune response against Wild-type Tat protein in a mouse
model.

The method for preparing recombinant proteins has been
described previously by the inventors (Ma, M. and Nath, A.
1997 J.V“1rol. 7112495; Nath,A. etal. 1996 J. Virol. 7011475;

20

DNA to express Tat protein in vivo. (Caselli, E. et al. 1999 J.
Immunol. 16215631). HoWever, the CTL responses to these
immunization strategies have been inadequate or remain

Nath, A. et al. 1996 J. Neurovirol. 2:17; Holden, C. P. et al.
1999 Neuroscience 9111369; Haughey, N. J. et al. 1998 J.
Neurovirol. 41353; Nath, A. et al. 2000 Ann. Neurol. 47;
Haughey, N. J. et al. 1999 J. Neurochem. 7311363). Brie?y,

Wild-type Tat 1-72 (SEQ ID NO: 1) and Tat 1-86 (SEQ ID
NO: 2), and mTat 1-86 (SEQ ID NO: 3) Were subcloned into

25

a bacterial vector PinPoint Xa-2 (Promega) to express Tat as

fusion proteins that are naturally biotinylated at the N-terrni
nus. E. Coli bacteria Were transformed With the resulting
vector, and Were groWn in 200 ml of Luria Broth for 18 hours
and in 2 L of Terri?c Broth for 1 hour. The cells Were har

30

206114345-47; Israel, Z. R. et al. 1999 AIDS Res. Hum.

Retroviruses 1511121), liposomes (Eckstein, M. et al. 1997
Vaccine 151220; Lutsiak, C. M. et al. 1998 J. Pharm. Sci.
8711428; Zheng, L. et al. 1999 AIDS Res. Hum. Retroviruses
1511011; Zhou, F. et al., 1992 J. Immunol., 14911599), and
35

column. It is obvious to those skilled in the art that the

genomic and amino acid sequence and length of Tat varies
amongst different strains of HIV. Also, the protein could be
produced in various strains of E. coli, other organisms or
cells.

uncharacterized. Alternatively, previous immunization proto
cols using particulate forms of antigen have induced strong T
cell proliferative responses. The previously devised particu
late delivery systems include polylactic acid-co-glycolic acid
(PLGA) microspheres (Cleland, J. L. et al. 1998 J. Pharm.
Sci. 8711489; Partidos, C. D. etal. 1997 J. Immunol. Methods

vested, and lysed, and the biotinylated Tat protein Was puri
?ed by a?inity chromatography using a soft release avidin
resin. Tat Was cleaved from the fusion protein by enzymatic
cleavage using factor Xa, eluted and desalted using a PD 10

ionic liposomes (Huang, L. et al. 1995, Biochem. Biophys.
Res. Commun. 2171761). Other vaccines have used plasmid

alginate microspheres (BoWersock, T. L. et al., 1999, Vaccine
1711803; BoWersock, T. L. etal., 1998, Immunol. Lett. 60137;
Cho, N. H. et al., 1998, J. Controlled Release 531215). HoW
ever, the disadvantages of the previously used particulate
systems include that that they are dif?cult and expensive for

40

large-scale production. Because the peptide antigen is encap

As mentioned above, the inventors have surprisingly dis
covered that bacterial RNA remains tightly associated With

sulated in the particulate delivery system during the manu
facturing process, the stability of the peptide must Withstand

the Tat proteins throughout the puri?cation process. In order
to avoid masking of Tat epitopes by bound bacterial RNA, the
recombinant Tat-bound RNA is removed by digestion With
RNAse. Endotoxin Was removed by adsorption onto poly

high-torque mechanical forces during the mixing step(s).
Control of optimal particle size, encapsulation ef?ciency and
separation of unencapsulated protein from the particulate
carrier are also problematic.
The present inventors have devised a particulate system

mixin B. The puri?ed Tat Was then stored as a 5% glycerol

stock at —800 C. The protein preparation Was analyzed by

that includes hydroxypropyl cellulose (HPC), Which forms
gel-particles containing Tat spontaneously at 35-370 C., and

Western blot and a LTR activation assay for purity, and for the

presence of endotoxin. Typically, the method described yields
0.5 mg of protein per liter of bacterial culture. The protein is

50

>98% pure, and contains less than 1 pg of endotoxin per gram

of Tat protein. The puri?ed Tat proteins Were used in all
processes of the present invention as described beloW.

In yet another aspect of the invention there is provided a

55

therapeutic composition for treating HIV infection, said com
position comprising an effective amount of an immunostimu
latory recombinant Tat protein and an adj uvant. Suitable com
60

composition, suitable for use in a method of treating early
HIV infection. Administering said protein evokes cellular and
humoral responses that lead to the elimination of HIV-in
fected cells at early stages of infection, such as during the

asymptomatic phase. While not Wishing to be bound by
theory, it is believed that this mode of action occurs by stimu

lating production of CTL, by stimulation of lytic cytokines by

to an animal induces signi?cant and speci?c humoral and T
cell responses. The present inventors assessed T cell and
antibody responses in groups of mice that had been immu
nized subcutaneously With Tat 1-72 alone or in combination

With one of the adj uvants1 Alum (aluminum hydroxide), HPC,
or ALUM+HPC. As shoWn in FIG. 2, signi?cant antibody

positions according to the present invention comprise a

physiologically acceptable or pharmacologically acceptable

avoids potentially damaging high-torque mechanical mixing
needed to entrap the antigen.
The present inventors have shoWn that administering an
immuno stimulatory recombinant Tat protein With an adjuvant

responses Were attained, in all four groups With the greatest
responses seen in the Tat+Alum and Tat+HPC+Alum groups.
The latter groups achieved a total anti-Tat antibody titre of

about 1 12000. Isotype speci?c ELISA revealed a predominant
IgG1 antibody response, and no detectable IgG2 antibodies.
65

This result indicates that Tat 1-72 elicits a substantial humoral

response. The inventors envision that several types of particu
late material including but not limited to the following: lipo
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somes, nanoparticles and microspheres may be used to gen

When Tat 1-72 or Tat 1-86 Were tested, neither protein caused

immunosuppression of systemic clonal expansion displayed

erate an immune response to Tat.

The auxiliary and inguinal lymph node cells of the mice

any immunosuppressive activity. A representative result is

immunized With Tat 1-72, Were isolated and cultured for 5
days in the presence or absence of Tat 1-72, and T cell pro
liferation Was determined by 3H-Tdr during the last 18 hours
of the 5-day incubation. The inventors discovered that Tat

shoWn in Example 2 and the accompanying FIG. 5.
The present inventors have also devised a nanoparticle

delivery system for delivering recombinant Tat protein. In
still another embodiment, the present invention provides Tat

1-72 immunization induces Tat-speci?c T cell proliferation
from the draining lymph nodes. (FIG. 3). The naive T cells
from the control group proliferated signi?cantly in response
to 15 ug/ml (1 uM) Tat 1-72, Which indicates that Tat 1-72 is

adsorbed nanoparticles. Tat-adsorbed nanoparticles are used

to improve both antibody production and cell-mediated
immune responses. It has also been shoWn that administering
an immuno stimulatory recombinant Tat protein With a nano

mitogenic at this concentration. In contrast T cells from Tat
1-72-immuniZed mice shoWed even greater proliferation in

particle-based vaccine delivery system to an animal induces
enhanced humoral and Thl-type cellular immune response.
The present inventors assessed antibody and T-cell responses
in groups of mice that had been immuniZed subcutaneously
With Tat 1-72 adjuvanted With Alum or lipid A, and Tat

the presence of 1 ug/ml concentration of Tat 1-72, indicating
that the proliferative T cell response is speci?c to the Tat

antigen. Therefore, recombinant Tat 1-72 is capable of induc
ing signi?cant and speci?c humoral and T cell mediated

adsorbed nanoparticles.

responses.
The immune system of the mouse is very similar to the

human immune system, and the person having skilled in the
art Will recogniZe that successful induction of anti-Tat
immune response in the mouse model is strongly predictive of

First, anionic nanoparticles Were prepared as previously
20

25

nuclease protection assay (Pharmingen) (FIG. 4). The cytok

enous milky slurry. Then, 300 ML of SDS stock solution (50
mM) Were added While stirring to obtain a ?nal SDS concen
30

Another embodiment of the present invention provides for

diluted With de-ioniZed and ?ltered (0.22 pm) Water and the
35

that neither Tat 1-72 nor Tat 1-86 produced by the foregoing
process (i.e. RNAse digestion and polymixin column treat
ment) shoW any immunosuppressive effects. This result is
surprising and unexpected. While not Wishing to be bound by
theory, it is believed that this result can be at least in part

tration of 15 mM. Within seconds, clear O/W microemulsions
formed. These microemulsions Were then simply cooled
(cured) to room temperature While stirring to form nanopar

ticles. For particle siZing, the nanoparticle suspension Was

a recombinant Tat protein that is not immunosuppressive.
Several studies cited above have shoWn that Tat is immuno

suppressive. HoWever, the present inventors have discovered

scintillation vials and melted on a hot plate at 50-550 C. Seven

hundred (700) ML of de-ioniZed and ?ltered (0.22 pm) Water
Were added to the melted Wax While stirring to form homog

ines expressed Were predominantly IL-4, IL-9, IL-13 With
relatively loW levels of INF-y, indicating a Th2 response. The
production of IgG1 and Th2 T cell response are consistent
With the knoWn Th2 inducing property ofAlum (Brewer, J. M.
et al. 1999 J. Immunol. 163:6448).

Protein On Engineered Nanoparticles Results In Enhanced
Immune Responses. Int J Pharrn. 2002 238 (1 -2):229-39,

incorporated herein by reference in its entirety. Brie?y, emul
sifying Wax (2 mg) Was accurately Weighed into 7-ml glass

a similarly effective immune response in humans.

To determine the cytokine pro?le of the Tat-speci?c T cells,
cytokine mRNA levels Were quantitated by multiprobe ribo

described in Cui, Z. and Mumper, R. J ., Coating of CationiZed

particle siZe Was measured at 900 light scattering for 90 s at

250 C. The Zeta potential of engineered nanoparticles Was
also measured using a Zeta SiZer 2000 from Malvern Instru

40

ments, Inc. (Southborough, Mass.).
The nanoparticles Were puri?ed using gel permeation chro
matography (GPC) With a Sephadex G-75 column. Varying
amounts of Tat in Water Were then added into the puri?ed

explained by differences betWeen the previously developed
experimental protocols and the protocol according to the

nanoparticle suspension folloWed by gently pipetting and

present invention, and in particular the absence from the

slightly vortexing. The mixtures Were then alloWed to stay on
laboratory bench for at least 30 min forbinding before further

inventive TAT 1-72 and Tat 1-86 of bacterial RNA and cyto
toxin, as Well as the retention of the folding structure of the

45 use.

recombinant proteins.

Then, the present inventors prepared Tat-adsorbed nano

particles.As used herein, “Tat-adsorbed nanoparticles” refers

The previous studies on the apoptotic effect of Tat Were
carried out in vitro, While the present inventors evaluated

Tat-induced immunosuppression in vivo using the in vivo
DO11.10 TCR transgenic T cell adoptive transfer system. In

50

to the adhesion of Tat protein to the surface of nanoparticles.
HIV-1 Tat is a small protein encoded by tWo exons. The basic
domain (aa 49-72) is rich in basic amino acids, Which ren

this system, T cells from mice that are sensitiZed to OVA are
transferred to a normal BALB/c mouse, and clonal expansion

dered the protein to be overall positively charged (K. A. Jones,

of antigen speci?c T cells in response to OVA or OVA that is
coinjected With a form of Tat, can be measured by How

Tat Was able to bind on the surface of the anionic nanopar

cytometry using clonotypic monoclonal antibody KJ1-26

B. M. Peterlin, Ann. Rev. Biochem. 1994 63 717). Therefore,

55

(Pape, K. et al. 1997 Immunol. Revl. 56:67). FolloWing adop
tive transfer of OVA speci?c D01 1.10 TCR transgenic cells
into normal BALB/ c mice, clonal expansion Was observed by
How cytometry of lymph node (LN) or spleen cells in
response to OVA immuniZation. This response is dependent

60

on OVA presentation in a class II restricted manner on APCs

approximately 100% as con?rmed by both gel permeation
chromatography and ultra?ltration (MW cut-off, 50 kDa).

and requires B7-CD28 interaction (Kearney, E. R. et al. 1995
J. Immunol. 155:1032). Because Tat 1-86 Was shoWn to sup

press the response to a coinjected antigen in another system
(Cohen, S. S. et al. 1999 Proc. Natl. Acad. Sci. USA
96110842), the inventors expected that Tat 1-86 Would also
suppress the response to OVA in their system. Surprisingly,

ticles via strong electrostatic interactions.As shoWn in FIG. 6,
the particle siZe and the Zeta potential of the nanoparticles
prior to protein binding Were 105111 nm and —65.1:2 mV,
respectively. With more Tat being adsorbed on the surface of
the nanoparticles, the siZe of the resulted nanoparticles
increased, and the Zeta potential of the nanoparticles became
less negative. At a ?nal Tat concentration of 25 ug/mL, the
adsorption ef?ciency of Tat to the anionic nanoparticles Was

This can be attributed to the fact that excess of anionic nano
65

particles Were used for adsorption. The Tat-adsorbed nano
particles Were stable in several simulated biological media as
shoWn in FIG. 7. It Was estimated that there Were approxi
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mately 6-7 Tat molecules being adsorbed on each nanopar

in 15 mL HBSS. The suspension Was then spun doWn at 1,500
rpm for 7 min at 4° C. After Washed once With 15 mL of

ticle (?nal Tat concentration, 25 pg/mL).

RPMI-1640 (BioWhittaker, Walkersville, Md.) supple

Further, the present inventors have shoWn that Tat adsorbed
nanoparticles result in enhanced humoral and Th-1 type
immune response. Both humoral and Th-l type cellular

mented With 10% fetal bovine serum (FBS) (Sigma, St.

immune responses Were assessed in groups of mice that had

the cells Were re-suspended in RPMI 1640 media (5 mL).

have been immuniZed subcutaneously With Tat 1-72 adju
vanted With Alum, Tat 1-72 adjuvanted With lipid A, and

Well) With three replicates (n:3) Were seeded into a 48-Well

Tat-adsorbed nanoparticles. Ten to tWelve Week old female

plate. (Costar), and stimulated With 2 pg/Well of Tat protein.

mice (Balb/C) from Harlan Sprague-DaWley Laboratories

Louis, Mo.) and 0.05 mg/mL of gentamycin (Gibco BRL),
For cytokine release, isolated splenocytes (1><106 cells/

(i) Tat (5 pg)-coated nanoparticles (15-20 pg), (ii) 5 pg of Tat

After incubation at 37° C. With 5% CO2 for 48 hours, the
splenocytes Were spun doWn and the supernatant Was col
lected and stored at —20° C. prior to further use. Cytokine
concentration (IFN-y and IL4) in the supematants Was deter

adjuvanted With 15 pg of Alum as a control for Th2 immune

mined using ELISA kits from Pierce-Endogen (Rockford,

responses, or (iii) 5 pg of Tat adjuvanted With 50 pg of lipidA

111.).

Were used for all animal studies.
Three groups of mice Were immuniZed With doses of either

For splenocyte proliferation, isolated splenocytes (1><106

as a control for Th1 immune responses. In addition, 5 naive
mice Were untreated and used as negative control. TWo hun

cells/Well) With three replicates (n:3) Were seeded into a
48-Well plate (Costar), and stimulated With 0 or 2 pg/Well of
Tat protein. After incubation at 37° C. With 5% CO2 for 96

dred (200) pl of each formulation in 10% lactose Was injected
on one site on the back. Prior to immuniZation, mice Were

anesthetiZed using pentobarbital (i.p.). On day 28, the mice
Were anesthetiZed and bled by cardiac puncture. Sera Were

hours, 60 pL of the combined MTS/PMS solution (Promega)
Was pipetted into each Well (20 pL/100 pL of cells in

separated and stored at —20° C. for assessment of antibody
and T cell proliferative responses.
After immunization and according to previously described
methods (Cui and Mumper, Int. J. Pharm. 2002 238 (1-2):

medium). After an additional 4.5 hours of incubation at 37° C.
With 5% CO2, the absorbance at 490 nm Was measured using
a Universal Microplate Reader. The cell proliferation Was
reported as the % increase of the OD490 of the stimulated cells

20
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229-39), the present inventors compared using ELISA Tat

(2 pg/Well) over the OD490 of un-stimulated cells (0 pg/Well)

speci?c antibodies (IgG and IgM) in serum of Tat-adsorbed
nanoparticles to Tat adjuvanted With Alum or lipidA. Brie?y,
Costar high binding 96-Well assay plates Were coated With 50
pL of Tat protein (8 pg /mL) overnight at 4° C. The plates Were

OD490un-st'imulated '

(i.e., 100><(OD490StimuZatefOD490un_s?mulated)/
30

then blocked for 1 hr at 37° C. With 4% bovine serum albumin

(BSA)/4% NGS (Sigma) solution (100 pL/Well) made in
1><PBS/TWeen 20 (Scytek). Mouse serum (50 pL/Well,
diluted for appropriate folds in 4% BSA/4% NGS/PBS/
TWeen 20) Was incubated for 2 hr at 37° C. After Washing
three times With PBS/Tween 20 buffer, anti-mouse IgG HRP

A representative result for Tat-adsorbed nanoparticle
cytokine release and cell proliferation are shoWn in Example
4 and the accompanying FIGS. 9 and 10.
Another embodiment of the present invention provides a
method for inhibiting HIV infection in an animal. Said

method comprises administering a pharmacologically active
35

amount of immuno stimulatory recombinant Tat protein to an

animal, preferably in a mammalian animal, and more prefer

F(ab')2 fragment from sheep or Goat Anti-Mouse IgM-HRP

ably in a human.

(Southern Biotechnology Associates, Inc., Birmingham,

In another aspect of the present invention, Tat-adsorbed
nanoparticles provides a delivery system for, and a method for

Ala.) (diluted 1:3,000 in 1% BSA) Was added (50 p/Well) and
incubated for 1 hr at 37° C. Plates Were Washed three times

40

Universal Microplate Reader (Bio-Tek Instruments, Inc.,
Winooski, Vt.) at 450 nm.
As shoWn in FIGS. 8A and 8B, the antibody titers-from
mice immuniZed With Tat-adsorbed nanoparticles, and Tat
adjuvanted With Alum or lipid A Were strong. The data
shoWed Tat-adsorbed nanoparticles Was comparable to that
from the mice immuniZed With Tat adjuvanted With Alum.

of cancer and infectious disease.

The present invention may be more fully appreciated upon

consideration of the folloWing, non-limiting, examples.
45

EXAMPLES

Example 1
50

The present example is provided to demonstrate the effec
tiveness of Tat 1-72 as an immunogen.
55

alone, Tat+Alum, Tat+HPC, or Tat+HPC+Alum. The mice
Were immuniZed subcutaneously at one-Week intervals for
three Weeks. At the end of the fourth Week, serum Was col

pooled together and placed into 5 mL of HBSS (Hank’s
Balanced Salt Solution) (1><) in a Stomacher Bag 400 from
60

eniZed at high speed for 60 s using a Stomacker HomogeniZer.
Cell suspensions Were then transferred into 15 mL Falcon
tube and ?lled to 15 mL With 1><ACK buffer (156 mM of

pouring off the supernatant, the cell pellet Was re-suspended

lected from each animal, and antibody and T cell proliferative
responses Were assessed. Tat speci?c antibodies Were

detected by sandWich ELISA on Tat coated ELISA plates, and

using rabbit-anti-mouse Ig secondary antibody. The results
are shoWn in FIGS. 2(A)-(D).

NH4Cl, 10 mM of KHCO3, and 100 pM of EDTA) for red
blood cell lysis. After 5-8 min at room temperature, the sus
pension Was spun doWn at 1,500 rpm for 7 min at 4° C. After

(a) To determine the immunogenicity of Tat 1-72, 4 groups
each of 5 mice Were immuniZed With 10 pg of puri?ed Tat

described above (Cui and Mumper, Int J. Pharm. 2002 238
(1-2)229-39). Brie?y, spleens from each group of mice Were

Fisher Scienti?c (Pittsburgh, Pa.). The spleens Were homog

Tat 1-72 Induces Humoral and Cell Mediated

Responses

To determine the cytokine release and the proliferation of
isolated splenocytes of Tat-adsorbed nanoparticles in com
parison to Tat adj uvanted With Alum and Tat adjuvanted With

lipid A, splenocyte preparation Was completed as previously

delivering, other protein antigens. The Tat-adsorbed nanopar
ticles delivery system is used in the treatment and prevention

With PBS/Tween 20 buffer. Finally, the samples Were devel
oped With 100 pL TMB substrate for 30 min at room tem
perature and then stopped With 50 pL of 0.2 M H2SO4. The
optical density (OD) of each Well Was measured using a

65

Signi?cant Tat-speci?c antibody responses Were obtained
in all four groups. The strongest response Was induced in the
tWo animal groups Which had been immuniZed With Tat in

US 7,588,764 B2
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combination WithAlum or HPC+Alum. The antibody titre for

induced in vivo clonal expansion of T cells. This result is

both groups Was 1:2000. Isotype-speci?c ELISA revealed a

represented by the 3.46% KJ-positive cells in the OVA mice
(FIG. 5B) versus the 0.57% in the control group (FIG. 5A).
The percentage KJ1-26 positive cells in the Tat 1-72 (FIG.
5C) and in the Tat 1-86 (FIG. 5D) Were not signi?cantly

predominant IgGl response, and no detectable IgG2 antibod
ies.

(b) To determine the ability of Tat 1-72 to induce Tat
speci?c T cell proliferation. Four groups each of 5 mice Were

different from the cells of group B. This result indicates that
neither Tat 1-72 nor Tat 1-86 did not suppress T cell prolif
eration in vivo.

immunized as described above. A ?fth group of mice Was
used as a control group, Which Was not immunized With Tat

1-72. The axilliary and inguinal lymph node cells Were iso
lated, and cultured for 5 days in the presence or absence of
either 1 ug/ml or 15 pg/ml Tat 1-72. Proliferation of the T cells

Example 3

Was determined as a function of incorporation of 3H-Tdr

Preparation of Tat-Adsorbed Nanoparticles

during the last 18 hours of incubation.

The present example is provided to describe the prepara
tion of Tat-adsorbed nanoparticles.

The results are shoWn in FIG. 3. Tat 1-72 induced prolif
eration of naive T cells from the control group at the Tat 1-72
concentration of 15 pg/ml. I pg/ml Tat 1-72 did not have a
signi?cant effect on the proliferation of the naive T cells.

Nanoparticles Were prepared as described above, having a

particle size and zeta potential prior to protein binding of

However, Tat 1-72 induced signi?cant increase in the prolif

105111 nm and —65.1:2 mV, respectively, as shoWn on FIG.

eration of the T cells from the Tat-immunized animals. The
signi?cant changes Were seen When either concentration of 1
pg/ml or 15 pg/ml Tat 1-72 Was used. This result indicates that
the proliferative response Was Tat 1-72-speci?c.

6. Tat protein Was adsorbed on the surface of the GPC puri?ed
20

anionic nanoparticles by gently mixing 25 pg/mL of Tat With
1 mL of GPC puri?ed nanoparticles in 10% lactose. The
Tat-adsorbed nanoparticles Were then co-incubated With

(c) To determine the cytokine pro?le of the proliferating T

either phosphate-buffered saline (PBS, 10 mM, pH7.4), fetal

cells, cytokine mRNA levels Were quantitated as folloWs.
Tat-immune T cells in culture Were incubated With 1 pg/ml
Tat 1-72 for three days. Total T cell RNA Was isolated by

guanidinium isothiocynate, and extracted using phenol. The

bovine serum (10%, v/v) in normal saline, or 10% (W/v)
lactose for 30 min at 370 C. The particle size stability Was
veri?ed in several simulated biological media prior to incu
bation (White bars) and after incubation (black bars) as shoWn

RNA Was hybridized to 32P-labelled RNA probes using the

on FIG. 7.

25

Pharmingen MCK-l multiprobe cytokine ribonuclease pro
tection kit. After hybridization, unprotected RNA Was

30

Example 4

digested using RNAse, and the protected fragments Were
resolved on a 8% polyacrylamide/urea sequencing gel. The

Tat-Adsorbed Nanoparticles Induces Enhanced

gel Was dried, and the RNA bands Were visualized and quan

Humoral and Cell Mediated Responses

titated using a Storm 860 phosphor imager.
The results of the assay are shoWn in FIG. 4, and shoW that
the cytokines that Were predominantly expresses Were IL-4,
IL-9 and IL-13. Relatively loW levels of INF-y Were also
observed.

35

The present example is provided to demonstrate the effec
tiveness of Tat-adsorbed nanoparticles.
(a) To determine the immunogenicity of Tat-adsorbed
nanoparticles, mice Were tWice immunized With either Tat (5

Example 2

40

pg) adsorbed on nanoparticles, or Tat (5 pg) adjuvanted With
lipidA (50 pg) on day 0 and day 14. On day 28, the mice Were

pg) adjuvanted With Alum (15 pg, GlaxoSmithKline), Tat (5
Tat 1-72 does not Induce Immunosuppression In
Vivo

sacri?ced. Mice Were harvested on day 28. A fourth group of
naive mice Were untreated and used as negative control. The
sera Were diluted as indicated prior to ELISA.

The present example is provided to shoW the utility of Tat

45

1-72 as an immunogen, Which does not induce immunosup

ShoWn in FIG. 8 are the Tat-speci?c antibody levels for IgG

(FIG. 8A) and IgM. (FIG. 8B) in serum. The antibody

pression.

responses Were strong since even after 10,000-fold of dilu

The applicants used the in vivo D01 1. 10 TCR transgenic
T cell adoptive transfer system to evaluate the effect of Tat
1-72 on the ability of D01 0. 11 T cells to undergo clonal
expansion in vivo. OVA-speci?c DO 10.11 TCR transgenic T

tion, the IgG titers from the immunized mice Were still 2.3
3 .0-fold greater than that from the naive mice. Moreover, the
antibody titers from mice immunized With the Tat-adsorbed
nanoparticles Were comparable to that from the mice immu

50

nized With Tat adjuvanted With Alum, a “gold” standard adju
vant for antibody induction. Statistical analyses (ANOVA)
did not reveal any signi?cant difference in both IgG and IgM

cells Were transferred to normal BALB/c mice, and clonal

expansion of the T cells Was evaluated folloWing administra
tion ofOVA in the presence or absence ofTat 1-72. D01 0.11

T cells, equivalent to 2.5><10 6 KJI 26, CD4+ cells, Were
transferred by intravenous administration into unirradiated
BALB/c mice. Three days later, three groups of mice Were
given 200 pg OVA peptide 323-339, OVA 323-339 in combi
nation With 10 pg Tat 1-72, or OVA 323-339 in combination
With 10 pg Tat 1-86. The injections Were repeated on tWo

55

among the three groups of immunized mice.

(b) To determine the cytokine pro?le of the proliferating T
cells, mice Were tWice immunized With either Tat (5 pg)

adjuvanted With Alum (15 pg, GlaxoSmithKline), Tat (5 pg)
60

consecutive days. Axillary and inguinal lymph node cells

adsorbed on nanoparticles, or Tat (5 pg) adjuvanted With lipid
A (50 pg) on day 0 and day 14. On day 28, the spleens Were
removed and splenocytes Were prepared as described above.

Were isolated on the third day. The cells Were stained With

The isolated splenocytes, (1 ><106 cells/Well) With three repli

KJI-26-FITC and anti-CD4-PE, and quantitated by How
cytometry.

cates (n:3) Were seeded into a 48-Well plate (Costar), and
stimulated With 2 pg/Well of Tat protein. After incubation With

The results are shoWn in FIG. 5. The numbers in the upper

right hand quadrants represent the percentage of KJ1-26,
CD4+ cells. Immunization With the OVA peptide alone

65

Tat (2 pg/5><106 cells) at 370 C. With 5% CO2 for 48 hours, the
splenocytes Were spun doWn and the supernatant Was col
lected and stored at —200 C. prior to further use. Naive mice

US 7,588,764 B2
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Were untreated and used as negative control. Cytokine con

(l ><l06 cells/Well) With three replicates (n:3) Were seeded

centration (lFN-y and 1L-4) in the supernatants Was deter

into a 48-Well plate (Costar), and stimulated With Tat (0 or 2
pg/5><l06 cells). After incubation With Tat at 37° C. With 5%
CO2 for 96 hours, 60 pL of the combined MTS/PMS solution
(Promega) Was pipetted into each Well (20 pL/l 00 pL of cells

mined using ELISA kits from Pierce-Endogen (Rockford,

Ill).
The results are shoWn in FIGS. 9 and 10. Strong and sig
ni?cant differences Were observed for the in vitro cytokine

release and proliferation of the isolated splenocytes among

in medium). After an additional 4. 5 hours of incubation at 37°
C. With 5% CO2, the absorbance at 490 nm Was measured

these three groups. The overall level of 1L-4 release Was loW
for all groups. More importantly, Alum as adjuvant led to the

Was reported as the % increase of the OD 490 of the stimulated

using a Universal Microplate Reader. The cell proliferation

highest 1L-4 release (FIG. 9B) and very Weak lFN-y release 10 cells (2 pg/Well) over the OD490 of un-stimulated cells (0

(FIG. 9A). Also, lipid A as adjuvant led to the highest lFN-y

pg/Well) (i.e., l00><(OD490S?muZatefOD490Mn_mmmated)/

release, an indication of Th1 immune responses (FIG. 9A).

OD490W_Sn-mmated). Naive mice Were untreated and used as

The nanoparticles adsorbed With Tat resulted in lFN-y level
negative control.
similar to that from the lipid A adjuvanted Tat and 33-fold
As shoWn in FIG. 10. Tat-adsorbed nanoparticles also
higher than that from the Alum adjuvanted Tat. This observa- 15 resulted in greater proliferation of isolated splenocytes than
tion, combined With the fact that the 1L-4 release from spleTat adjuvanted WithAlum, an indication of enhanced memory
nocytes isolated from mice immuniZed With the nanoparticles
adsorbed With Tat Was signi?cantly loWer than that from mice

immune response from the nanoparticles. There Was no dif
ference betWeen the Naive and the Alum groups.

immuniZed With Alum adjuvanted Tat, strongly suggested

The foregoing illustrative examples are provided to dem

that the Tat-adsorbed nanoparticles led to Thl biased immune 20 onstrate the principles of the invention, and are not intended
responses.
to be limiting. One of skill in the art Will recogniZe that

(c) To determine the ability of Tat-adsorbed nanoparticles
to induce Tat-speci?c T-cell proliferation, mice Were tWice
immuniZed With either Tat (5 pg) adjuvanted With Alum (l 5
pg, GlaxoSmithKline), Tat (5 pg) adsorbed on nanoparticles, 25

additional embodiments are possible Within the scope of the
present invention, and the presentation of the foregoing
examples is not meant to imply limitation of the invention to
the examples.

or Tat (5 pg) adjuvanted With lipidA (50 pg) on day 0 and day

All references cited herein, including patents, patent appli

14 On day 28, the spleens Were removed and splenocytes
Were prepared as described above. The isolated splenocytes

cations and non-patent literature references, are expressly
incorporated herein by reference.

SEQUENCE LISTING

<l60> NUMBER OF SEQ ID NOS: 3

<211> LENGTH: 72
<212> TYPE: PRT
<213> ORGANISM: HIV

<4oo> SEQUENCE:

1

Met Glu Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser
1

5

1o

15

Gln Pro Lys Thr Ala Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Phe
2o

25

30

His Cys Gln Val Cys Phe Ile Thr Lys Ala Leu Gly Ile Ser Tyr Gly
35

4o

45

Arg Lys Lys Arg Arg Gln Arg Arg Arg Ala His Gln Asn Ser Gln Thr
5o

55

60

His Gln Ala Ser Leu Ser Lys Gln
65

7o

<211> LENGTH: 86
<212> TYPE: PRT
<213> ORGANISM: HIV

<4oo> SEQUENCE: 2

Met Glu Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser
1

5

1o

15

Gln Pro Lys Thr Ala Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Phe
2o

25

30

His Cys Gln Val Cys Phe Ile Thr Lys Ala Leu Gly Ile Ser Tyr Gly
35

4o
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